BVF Inc. IL Decreases Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

BVF Inc. IL lessened its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 63.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,670,642 shares of the company's stock after selling 4,712,000 shares during the period. BVF Inc. IL owned 5.78% of 4D Molecular Therapeutics worth $14,875,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Barclays PLC increased its stake in shares of 4D Molecular Therapeutics by 141.0% in the third quarter. Barclays PLC now owns 114,848 shares of the company's stock valued at $1,241,000 after buying an additional 67,202 shares during the period. Rhumbline Advisers increased its position in 4D Molecular Therapeutics by 5.3% in the 4th quarter. Rhumbline Advisers now owns 73,431 shares of the company's stock valued at $409,000 after acquiring an additional 3,675 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of 4D Molecular Therapeutics by 139.2% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,354 shares of the company's stock valued at $364,000 after acquiring an additional 38,031 shares during the last quarter. Proficio Capital Partners LLC increased its holdings in 4D Molecular Therapeutics by 100.0% in the fourth quarter. Proficio Capital Partners LLC now owns 20,000 shares of the company's stock valued at $111,000 after purchasing an additional 10,000 shares during the period. Finally, Vanguard Group Inc. raised its position in 4D Molecular Therapeutics by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company's stock worth $15,933,000 after purchasing an additional 92,791 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. BMO Capital Markets cut 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $40.00 to $15.00 in a research note on Monday, January 13th. Leerink Partners lowered their price target on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an "outperform" rating for the company in a report on Monday, January 13th. Royal Bank of Canada reduced their price objective on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd. Weiss Ratings reissued a "sell (e+)" rating on shares of 4D Molecular Therapeutics in a research note on Thursday, April 24th. Finally, HC Wainwright restated a "buy" rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $29.89.

4D Molecular Therapeutics Trading Down 5.9 %

4D Molecular Therapeutics stock traded down $0.19 during trading on Friday, hitting $3.05. 776,054 shares of the company were exchanged, compared to its average volume of 831,749. The company has a market capitalization of $141.29 million, a P/E ratio of -1.07 and a beta of 2.87. The business's 50 day moving average is $3.40 and its 200 day moving average is $5.33. 4D Molecular Therapeutics, Inc. has a 52 week low of $2.24 and a 52 week high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02). Equities analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.